Calendar

Aug
14
Fri
CATALYST: A Virtual Reality View of Genomics, Targeted Therapeutic Options, and Treatment Sequencing for the Management of Hematologic Malignancies
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

CATALYST: A Virtual Reality View of Genomics, Targeted Therapeutic Options, and Treatment Sequencing for the Management of Hematologic Malignancies

View Activity

FACULTY

Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood
Disorders
Levine Cancer Institute
Charlotte, NC

Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

PROGRAM OVERVIEW

This online activity will cover the treatment and management of patients with AML and CLL.

TARGET AUDIENCE

This activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in
the treatment of CLL and AML.

LEARNING OBJECTIVES

On completing this program, attendees should be able to:

  • Explain how common mutations and abnormalities in patients with previously untreated and relapsed/refractory
    (R/R) CLL and AML affect treatment decision-making
  • Describe available and emerging therapeutic approaches for patients with previously untreated and R/R CLL and
    AML
  • Review methods for measuring and analyzing minimal residual disease (MRD) in CLL and clinical trial data
    providing insight into the use of MRD status in the management of CLL
  • Design evidence-based therapeutic strategies for patients with previously untreated and R/R CLL and AML based on
    patient characteristics
  • Discuss the benefits of effective communication between health care providers and patients with previously
    untreated and R/R CLL and AML

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with AML and CLL.

CNE Credits:
2.0 ANCC Contact Hours

CNE ACCREDITATION STATEMENTS:
Ultimate Medical Academy/Completed Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial
Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity,
and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an
MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the
manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an
educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Michael Grunwald has received consultant fees from Incyte, BMS/Celgene, Pfizer, Cardinal Health,
Amgen, Merck, Agios, AbbVie, Daiichi Sankyo, Trovagene, Astellas, and Premier, and received fees for non-CME
services from Incyte. He has been contracted for research for Amgen, Incyte, Genentech/Roche, Janssen, Forma
Therapeutics, and Novartis. He has ownership interest in Medtronic.

Dr. Ryan Jacobs has served on the speakers’ bureau for AbbVie, AstraZeneca, Pharmacyclics, Genentech, Janssen, and Verastem. He has received consultant fees from AbbVie, Pharmacyclics, Verastem, and AstraZeneca. He has received research funding from Pharmacyclics and TG Therapeutics.

CME Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing
any unlabeled or investigational use of any commercial product or device not yet approved for use in the United
States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the activity.
  3. Complete pre-and post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: August 14, 2020

EXPIRATION DATE: August 14, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at
info@medlearninggroup.com

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only.
Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Nov
4
Wed
Targeting Therapy in Acute Myeloid Leukemia (AML): Improving the Management of Treatment-Naïve Patients in the Department of Veterans Affairs
Nov 4 2020 @ 12:00 am – Nov 4 2021 @ 11:45 pm

Targeting Therapy in Acute Myeloid Leukemia (AML): Improving the Management of Treatment-Naïve Patients in the Department of Veterans Affairs

View Activity

 

PROGRAM CHAIR & FACULTY PRESENTER

Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC

PROGRAM OVERVIEW

This activity will cover the management of patients with treatment-naïve AML.

EDUCATIONAL AUDIENCE

This educational activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of treatment-naïve AML.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Explain how common mutations and abnormalities in patients with previously untreated AML affect treatment decision-making and management strategies
  • Evaluate the efficacy and safety of available and emerging therapeutic approaches for patients with previously untreated AML
  • Incorporate diagnostic and evidence-based therapeutic strategies for patients with previously untreated AML
  • Discuss the benefits of effective communication between health care providers and patients with previously untreated AML

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with AML.

CNE Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Michael Grunwald has received consultant fees from Incyte, BMS/Celgene, Pfizer, Cardinal Health, Amgen, Merck, Agios, AbbVie, Daiichi Sankyo, Trovagene, Astellas, and Premier, and received fees for non-CME services from Incyte. He has been contracted for research for Amgen, Incyte, Genentech/Roche, Janssen, Forma Therapeutics, and Novartis. He has ownership interest in Medtronic.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Marcello A. Morgan, MD, MPH, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the evaluation form.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only.
Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Nov
6
Fri
CLL Grand Rounds @ SUNY Downstate Medical Center
Nov 6 @ 9:00 am – 10:00 am

Location
SUNY Downstate Medical Center
Brooklyn, NY

Speaker

Nov
10
Tue
AML Grand Rounds @ Richmond University Medical Center
Nov 10 @ 8:00 am – 9:00 am

11/10/20
8-9am

Location
Richmond University Medical Center
Staten Island, NY

Speaker
Michael Grunwald, MD

Nov
13
Fri
AML Grand Rounds @ SUNY Downstate Medical Center
Nov 13 @ 9:00 am – 10:00 am

Location
SUNY Downstate Medical Center
Brooklyn, NY

Speaker

Nov
16
Mon
AML Grand Rounds @ Thomas E. Creek VA Medical Center
Nov 16 @ 12:00 pm – 1:00 pm

Location
Thomas E. Creek VA Medical Center
Amarillo, TX

Speaker

CLL Grand Rounds @ Moffitt Cancer Center
Nov 16 @ 2:00 pm – 3:00 pm

Location
Moffitt Cancer Center
Tampa FL

Speaker
Ryan Jacobs, MD

AML Grand Rounds @ Moffitt Cancer Center
Nov 16 @ 3:00 pm – 4:00 pm

Location
Moffitt Cancer Center
Tampa FL

Speaker
Michael Grunwald, MD